SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Viking Therapeutics, Inc. (VKTX)

VKTX RSS Feed
Add VKTX Price Alert      Hide Sticky   Hide Intro
Moderator: greens12, BrazenBull
Search This Board: 
Last Post: 10/16/2017 8:14:29 PM - Followers: 29 - Board type: Free - Posts Today: 21

 
Novel therapeutics for metabolic<Br/>and endocrine disorders
  1. 2
    2
    2
     
 

VK0612

Viking Therapeutics is focused on the development of novel therapeutics for patients suffering from metabolic and endocrine disorders.

Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of patients recovering from non-elective hip fracture surgery. The Company’s second program is focused on the development of first-in-class, selective, small molecule agonists of the thyroid receptor beta, or TRß, for adrenoleukodystrophy, or ALD, and lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis, or NASH. Viking is also developing additional programs targeted at diabetes, metabolic diseases and anemia.
 

Overview

Pills

We have a portfolio of five drug candidates in clinical trials or preclinical studies

Our lead clinical program, VK5211, is a novel, orally available, non-steroidal selective androgen receptor modulator, or SARM, in development for the treatment of patients recovering from non-elective hip fracture surgery. VK5211 is designed to produce the therapeutic benefits of testosterone in muscle and bone with improved safety, tolerability and patient acceptance. We have initiated a Phase 2 clinical trial with VK5211 in patients recovering from non-elective hip fracture surgery. For more information on this study please visit NCT02578095.

Our second pipeline program is focused on the development of novel small molecule agonists of the thyroid beta (TRb) receptor, VK2809 and VK0214. These novel TRb agonists are being developed for hypercholesterolemia and fatty liver disease and X-linked adrenoleukodystrophy, or X-ALD. We have initiated Phase 2 clinical development of VK 2809 in hypercholesterolemia and fatty liver disease. VK0214 is in preclinical development for X-ALD.

We are also developing VK0612, a first-in-class, orally available drug 

SureTrader
Interactive Brokers Advertisement
VKTX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VKTX News: Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleuko... 10/04/2017 07:05:00 AM
VKTX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 09/29/2017 04:46:11 PM
VKTX News: Current Report Filing (8-k) 09/29/2017 07:06:35 AM
VKTX News: Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital 09/29/2017 07:05:00 AM
VKTX News: Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settin... 09/25/2017 07:30:00 AM
PostSubject
#840   Lmmaaaooooo. Lynx7 10/16/17 08:14:29 PM
#839   Without having the benefit of hearing your convo ZeWaffleBaron 10/16/17 04:44:53 PM
#838   Company blinded .. I asked them .. if zoomlik 10/16/17 03:22:13 PM
#837   The IBB is green right now still up...Trump greens12 10/16/17 01:52:05 PM
#836   Exactly right. What usually happens is they ZeWaffleBaron 10/16/17 01:25:07 PM
#835   Yes. https://www.bloomberg.com/amp/news/articles/2017-10-16/trump-s-new-talk-on Titan V 10/16/17 01:08:58 PM
#834   Fair point. But didn't they voluntarily stop recruiting Titan V 10/16/17 01:07:47 PM
#833   Anyways .. sell off today appears profit taking zoomlik 10/16/17 01:06:31 PM
#832   It will not be a total fail .. zoomlik 10/16/17 01:05:50 PM
#831   That would be odd and unlikely IMO. Whenever Titan V 10/16/17 11:50:16 AM
#830   I get it ...I'm not worried about Random greens12 10/16/17 11:30:39 AM
#829   You just don't get it .. sorry zoomlik 10/16/17 11:28:38 AM
#828   The company had their own data already before greens12 10/16/17 11:28:09 AM
#827   But i thought you said the study was greens12 10/16/17 11:24:13 AM
#826   http://www.investopedia.com/terms/s/statistically_significant.asp zoomlik 10/16/17 11:13:37 AM
#825   still not sure what you are refering to... greens12 10/16/17 11:11:46 AM
#824   Stat significant .. p less than 0.5 zoomlik 10/16/17 11:08:31 AM
#823   What is SS ? greens12 10/16/17 11:08:00 AM
#822   Data maybe ok but not SS .. so zoomlik 10/16/17 11:05:49 AM
#821   The CEO needs to get VK5211 data out greens12 10/16/17 11:04:20 AM
#820   I think stock is being held back coz zoomlik 10/16/17 08:57:04 AM
#819   Thyroid Hormone Receptor Beta in the Ventromedial Hypothalamus Titan V 10/15/17 02:42:41 PM
#818   Not major readouts but should warm up the Titan V 10/14/17 01:38:14 PM
#817   Additionally, Titan V 10/14/17 11:36:31 AM
#816   VK0214 data will be presented at the 87th greens12 10/14/17 02:09:14 AM
#815   Solid week , held most of the gains, greens12 10/13/17 10:04:48 PM
#814   If vk5211 and vk2809 have good P2 greens12 10/13/17 11:12:10 AM
#813   Correction .. $17 a share .. so SARM zoomlik 10/13/17 09:43:15 AM
#812   In mdgl terms, vktx should be $12 .. zoomlik 10/13/17 08:43:01 AM
#811   I liked this article with a Biotech Investor greens12 10/12/17 10:02:52 PM
#810   Lol Greens, well said! Really happy to ZeWaffleBaron 10/12/17 07:46:00 PM
#809   I am grateful for todays red candle, and BrazenBull 10/12/17 03:44:40 PM
#808   My calculations July 12th PR add 12 weeks greens12 10/12/17 01:36:03 PM
#807   Picked up some more just now. Looking forward Titan V 10/12/17 01:31:18 PM
#806   agreed, I think a partnership is on the greens12 10/12/17 12:14:15 PM
#805   If VK5211 data is positive, I think they Titan V 10/12/17 12:12:27 PM
#804   Thank you both .. zoomlik 10/12/17 12:02:49 PM
#803   VK5211 is projected have a Billion dollars in greens12 10/12/17 11:51:34 AM
#802   "and quality is compromised more than likely" That greens12 10/12/17 11:46:24 AM
#801   The hype on Sarms isn’t commercialization the hype Lynx7 10/12/17 11:36:39 AM
#800   Thanks .. SARM parents run mid 2025 .. zoomlik 10/12/17 11:34:30 AM
#799   *vk2809 and yes there is more value in Lynx7 10/12/17 10:45:40 AM
#798   No Sarms are not available over the counter. Lynx7 10/12/17 10:44:17 AM
#797   Isn't ligand SARM already avail over counter? So vktx zoomlik 10/12/17 09:51:42 AM
#796   Putting too much emphasis on SARM .. Action zoomlik 10/11/17 11:44:32 AM
#795   Its Golden cross time http://stockcharts.com/h-sc/ui?s=VKTX greens12 10/11/17 11:24:53 AM
#794   Hey buddy I'm here, patiently waiting in the ZeWaffleBaron 10/11/17 10:47:06 AM
#793   Good for almost another 10 years. BrazenBull 10/11/17 10:33:07 AM
#792   Not a vktx fundamental geek .. but, Isn't zoomlik 10/11/17 09:23:05 AM
#791   Brother we are on the cusp of the BrazenBull 10/11/17 01:37:47 AM
PostSubject